While no food can be positioned as a standalone treatment for neurodegenerative conditions, the consistency of findings across multiple studies makes EVOO one of the most studied dietary factors in cognitive health — a distinction that carries weight in a field where evidence-backed nutritional interventions remain scarce.
Blood sugar regulation: a third front for a well-documented oil
Beyond cardiovascular and cognitive benefits, extra-virgin olive oil has also been linked to improved blood sugar balance. This is particularly relevant given the global rise in type 2 diabetes and the growing body of research connecting dietary fat quality to insulin sensitivity.
The monounsaturated fats in EVOO are thought to slow glucose absorption and improve the body’s response to insulin, helping to moderate post-meal blood sugar spikes. This metabolic effect complements its anti-inflammatory properties, since chronic inflammation is also implicated in insulin resistance.
For anyone monitoring their metabolic health — whether managing a diagnosis or working to reduce long-term risk — incorporating genuine extra-virgin olive oil as a primary cooking and dressing fat represents one of the more straightforward, evidence-supported dietary adjustments available.
The next phase of research on oleocanthal is expected to clarify the precise dosage and duration of EVOO consumption needed to produce measurable effects on amyloid plaque clearance — a question that several ongoing neurological trials are actively investigating. On the cardiovascular side, updated follow-up data from the PREDIMED cohort is anticipated to shed further light on long-term outcomes beyond the initial trial period. For consumers, the more immediate open question is one of supply chain transparency: as demand for certified EVOO grows, regulators in the EU and the US are under increasing pressure to tighten labelling standards and close the loopholes that allow mislabelled refined oils to reach shelves under the extra-virgin designation.
